Leadership Team

Deep knowledge in advancing drug development.

Our team is comprised of world-class scientific advisors, clinicians and innovation leaders. They have the strategic ability to put key pieces in place for driving clinical development forward.

Board Committees

Independent Directors Audit Compensation Nominating and Corporate Governance

Eric J. Ende, M.D., M.B.A

Herbert Conrad

James S. Scibetta

Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A.

Natasha Giordano

Kathryn Penkus Corzo

Chair
Member

Scientific Advisory Board

Infectious Disease Experts - MAT2203

Prof. Oliver Cornely, M.D., FACP, FIDSA

Professor of Internal Medicine and Attending Physician, Uniklinik Köln

Dimitrios P. Kontoyiannis, M.D., M.S., Sc.D., PhD (Hon),FACP, FIDSA, FECMM

Professor in the Department of Infectious Diseases Infection Control and Employee Health, The University of Texas

Peter G. Pappas, M.D., FACP

Professor of Medicine, University of Alabama

David S. Perlin, Ph.D.

Executive Director, New Jersey Medical School (NJMS), Rutgers Biomedical and Health Sciences

Infectious Disease Experts - MAT2501

Charles L. Daley, M.D.

Chief, Division of Mycobacterial & Respiratory Infections at National Jewish Health

Patrick A. Flume, M.D.

Director, Adult Cystic Fibrosis Center at Medical University of South Carolina

Donald VanDevanter, Ph.D.

Adjunct Professor of Pediatrics at Case Western Reserve University School of Medicine